PEN Stock: Penumbra, Inc. Stock Price, Analysis & Insights
Get live pen stock price $311.81, comprehensive Penumbra, Inc. stock analysis, charts, news, and expert forecast. Real-time pen stock data and investment insights.
Loading chart...
Company Overview
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Company Information
- CEO
- Adam Elsesser
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 4500
Contact Information
- Website
- https://www.penumbrainc.com
- Address
- One Penumbra Place
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 74.2)
✓ Lower volatility stock (Beta: 0.66) may provide portfolio stability
Business Model & Strategy
Penumbra, Inc. operates in the Medical - Devices industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Adam Elsesser, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Devices model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Penumbra, Inc. competes in the Medical - Devices within the broader Healthcare. With 12.2 billion in market capitalization, the company is positioned as a established player in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Penumbra, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Penumbra, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Penumbra, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Penumbra, Inc.
- ⚠Investors should consider how Penumbra, Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 74.2) requires strong growth to justify
Market Cap
12.21B
P/E Ratio
74.24
Beta
0.66
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 12.21B market capitalization
- Trading Volume: 62.22K shares traded today
- Price Range: 52-week range of $221.26 - $315.74
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Penumbra, Inc.
Penumbra, Inc. (PEN) operates in the Medical - Devices industry within the Healthcare sector. With a current market capitalization of 12.21B, the company represents a significant player in its market. The stock is currently trading at $311.81 with a positivedaily change of 1.20%.
The company's 4500 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 74.24, beta of 0.66, and 52-week price range from $221.26 to $315.74when evaluating investment opportunities.
Why Invest in Penumbra, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Adam Elsesser
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.